Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …

''It seems more than ever likely that blood-derived stem tive capacity. 47-49 In the allogeneic
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …

Anticancer chemotherapy drugs challenge hematopoietic tissues to regenerate but
commonly produce long-term sequelae. Chemotherapy-induced deficits in hematopoietic …

PURPOSE To analyze factors that affect the collection of peripheral-blood stem cells (PBSC)
before transplant and the tempo of engraftment after transplant. PATIENTS AND METHODS …

The purpose of this article was to examine historic institutional autologous stem cell
mobilization practices and evaluate factors influencing mobilization failure and kinetics. In …

Categorizing prognostic variables is essential for their use in clinical decision‐making. Often
a single cutpoint that stratifies patients into high‐risk and low‐risk categories is sought …

As more efficient agents for stem cell mobilization are being developed, there is an urgent
need to define which patient population might benefit from these novel drugs. For a precise …

Transfusion of autologous peripheral blood stem cells (PBSCs) of good quality ensures fast
hematopoietic engraftment after myeloablative therapy with a decrease in procedure-related …

Purpose: To review recent advances in peripheralblood progenitor-cell (PBPC)
transplantation in order to define the optimal cell dose required for autologous and …

Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization.
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …